About Medical Device Company

Medical Assist Devices for Everyday Use

KX2 medical device company develops, manufactures, and sells assistive devices that address mobility issues—such as Foot Drop—and other medical assistance needs.

foot drop foot brace KX2 medical devices 1
Stand Up Portable Urinal Holder

About KX2 Medical Devices Company

James M. Killian founded KX2 devices. He is an experienced neurologist with many years of experience in clinical practice.

After observing and repeatedly hearing firsthand the failures of other assistive devices available on the market, he was compelled to create product solutions that more adequately met the practical needs of his patients (and others living with mobility issues).

A small, woman-owned business, KX2 medical devices company contracts with an established soft-goods manufacturer in the United States. This relationship has led to unique, problem-based solutions. The manufacturer is certified by ISO 9001 and ISO 13485 and produces consistent, high-quality products.

Our most popular product, The Flexible Foot Lift, is a foot and ankle brace for drop feet. It promotes natural walking/movement, is comfortable to wear, can be worn on both left and right feet, and can be worn with any shoe. Our newest product, the Stand-Up Portable Urinal Holder, is a urinal bottle holder that attaches to a standard walker and allows a person to urinate with or without assistance.

James M. Killian, M.D.


Our Founder

James M. Killian founded KX2 devices. He is an experienced Neurologist with many years in clinical practice. He was compelled to create product solutions that more adequately met the practical needs of his patients (and others living with mobility issues) after observing and repeatedly hearing firsthand the failures of other assistive devices available on the market.


  • REMG and Nerve Conduction Studies
  • RMusculoskeletal Disorders
  • RNeuromuscular Diseases
  • RPeripheral Neuropathy


  • RAmerican Board of Psychiatry and Neurology, Neurology
  • RAmerican Board of Electrodiagnostic Medicine, Electrodiagnostic Medicine


  • RM.D., Medical College of Wisconsin, Milwaukee, Wis.
  • RInternship, Internal Medicine, Charity Hospital of Louisiana, New Orleans, La.
  • RResidency, Neurology, Charity Hospital and Tulane School of Medicine, New Orleans, La.
  • RFellowship, Neurology, Tulane University School of Medicine, New Orleans, La.
  • RFellowship, , National Hospital for Nervous Diseases, Queen's Square, London, United Kingdom

Peripheral neuropathy; EMG and nerve conduction studies in the evaluation of neuromuscular and musculoskeletal
disorders; Neuromuscular ultrasound

  • Bonadonna F, Killian JM. A knowledge-based system for evaluation of CIDP diagnostic criteria in a database with 26,000 nerve conduction studies: Computer-aided creation of heuristic rules and discovery of new diagnostic criteria. Frontiers in ICT. 2015;2(26):. DOI: 10.3389/fict.2015.00026.
  • Jones K, Wei C, Iakova P, Bugiardini E, Schneider-Gold C, Meola G, et al. GSK3beta mediates muscle pathology in myotonic dystrophy. J Clin Invest. 2012;122(12):4461-72. PMID: 23160194.
  • Killian JM, Smyth S, Guerra R, Adhikari I, Harati Y. Comparison of sudomotor and sensory nerve testing in painful sensory neuropathies. J Clin Neuromuscul Dis. 2011;12(3):138-42. PMID: 21321492.
  • Ward AJ, Rimer M, Killian JM, Dowling JJ, Cooper TA. CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1. Hum Mol Genet. 2010;19(18):3614-22. PMID: 20603324.
  • Chen M, Chen G, Nie H, Zhang X, Niu X, Zang YC, et al. Regulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4+ T Cells in MS. Eur J Immunol. 2009;39(9):2525-36. PMID: 19670379.
  • Hong J, Li H, Chen M, Zang YC, Skinner SM, Killian JM, et al. Regulatory and pro-inflammatory phenotypes of myelin basic protein-autoreactive T cells in multiple sclerosis. Int Immunol. 2009;21(12):1329-40. PMID: 19822525.
  • Zang YC, Li S, Rivera VM, Hong J, Robinson RR, Breitbach WT, et al. Increased CD8+ cytotoxic T cell responses to myelin basic protein in multiple sclerosis. J Immunol. 2004;172(8):5120-7. PMID: 15067096.
  • Smith RG, Roher AE, Appel SH, Doody RS, Killian JM, Corey-Bloom J, et al. Autonomic sudomotor dysfunction in Alzheimer’s disease. Curr Med Chem – Imun Endoc Metab Agents. 2003;3(1):77-84.
  • Zang YC, Hong J, Rivera VM, Killian J, Zhang JZ. Human anti-idiotypic T cells induced by TCR peptides corresponding to a common CDR3 sequence motif in myelin basic protein-reactive T cells. Int Immunol. 2003;15(9):1073-80. PMID: 12917259.
  • Tejada-Simon MV, Zang YC, Hong J, Rivera VM, Killian JM, Zhang JZ. Detection of viral DNA and immune responses to the human herpesvirus 6 101-kilodalton virion protein in patients with multiple sclerosis and in controls. J Virol. 2002;76(12):6147-54. PMID: 12021348.
  • Zhang JZ, Rivera VM, Tejada-Simon MV, Yang D, Hong J, Li S, et al. T cell vaccination in multiple sclerosis: Results of a preliminary study. J Neurol. 2002;249(2):212-8. PMID: 11985389.
  • Killian JM, Foreman PJ. Clinical utility of dorsal sural nerve conduction studies. Muscle Nerve. 2001;24(6):817-20. PMID: 11360266.
  • Hong J, Zang YC, Tejada-Simon MV, Li S, Rivera VM, Killian J, et al. Reactivity and regulatory properties of human anti-idiotypic antibodies induced by T cell vaccination. J Immunol. 2000;165(12):6858-64. PMID: 11120809.
  • Tejada-Simon MV, Zang YC, Yang D, Hong J, Li S, Singh RA, et al. Aberrant T cell responses to myelin antigens during clinical exacerbation in patients with multiple sclerosis. Int Immunol. 2000;12(12):1641-50. PMID: 11099303.
  • Zang YC, Hong J, Rivera VM, Killian J, Zhang JZ. Preferential recognition of TCR hypervariable regions by human anti-idiotypic T cells induced by T cell vaccination. J Immunol. 2000;164(8):4011-7. PMID: 10754292.
  • Zang YC, Hong J, Tejada-Simon MV, Li S, Rivera VM, Killian JM, et al. Th2 immune regulation induced by T cell vaccination in patients with multiple sclerosis. Eur J Immunol. 2000;30(3):908-13. PMID: 10741408.
  • Hong J, Zang YC, Tejada-Simon MV, Kozovska M, Li S, Singh RA, et al. A common TCR V-D-J sequence in V beta 13.1 T cells recognizing an immunodominant peptide of myelin basic protein in multiple sclerosis. J Immunol. 1999;163(6):3530-8. PMID: 10477628.
  • Kozovska ME, Hong J, Zang YC, Li S, Rivera VM, Killian JM, et al. Interferon beta induces T-helper 2 immune deviation in MS. Neurology. 1999;53(8):1692-7. PMID: 10563614.
  • Potocki L, Chen KS, Koeuth T, Killian J, Iannaccone ST, Shapira SK, et al. DNA rearrangements on both homologues of chromosome 17 in a mildly delayed individual with a family history of autosomal dominant carpal tunnel syndrome. Am J Hum Genet. 1999;64(2):471-8. PMID: 9973284.
  • Zang YC, Kozovska MM, Hong J, Li S, Mann S, Killian JM, et al. Impaired apoptotic deletion of myelin basic protein-reactive T cells in patients with multiple sclerosis. Eur J Immunol. 1999;29(5):1692-700. PMID: 10359124.
  • Greenberg F, Lewis RA, Potocki L, Glaze D, Parke J, Killian J, et al. Multi-disciplinary clinical study of Smith-Magenis syndrome (deletion 17p11.2). Am J Med Genet. 1996;62(3):247-54. PMID: 8882782.
  • Killian JM, Tiwari PS, Jacobson S, Jackson RD, Lupski JR. Longitudinal studies of the duplication form of Charcot-Marie-Tooth polyneuropathy. Muscle Nerve. 1996;19(1):74-8. PMID: 8538673.
  • Warner LE, Hilz MJ, Appel SH, Killian JM, Kolodry EH, Karpati G, et al. Clinical phenotypes of different MPZ (P0) mutations may include Charcot-Marie-Tooth type 1B, Dejerine-Sottas, and congenital hypomyelination. Neuron. 1996;17(3):451-60. PMID: 8816708.
  • Killian JM, Wilfong AA, Burnett L, Appel SH, Boland D. Decremental motor responses to repetitive nerve stimulation in ALS. Muscle Nerve. 1994;17(7):747-54. PMID: 8008001.
  • Roa BB, Garcia CA, Pentao L, Killian JM, Trask BJ, Suter U, et al. Evidence for a recessive PMP22 point mutation in Charcot-Marie-Tooth disease type 1A. Nat Genet. 1993;5(2):189-94. PMID: 8252046.
  • Zori RT, Lupski JR, Heju Z, Greenberg F, Killian JM, Gray BA, et al. Clinical, cytogenetic, and molecular evidence for an infant with Smith-Magenis syndrome born from a mother having a mosaic 17p11.2p12 deletion. Am J Med Genet. 1993;47(4):504-11. PMID: 8256814.
  • Lupski JR, de Oca-Luna RM, Slaugenhaupt S, Pentao L, Guzzetta V, Trask BJ, et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell. 1991;66(2):219-32. PMID: 1677316.
  • Engelhardt JI, Appel SH, Killian JM. Motor neuron destruction in guinea pigs immunized with bovine spinal cord ventral horn homogenate: Experimental autoimmune gray matter disease. J Neuroimmunol. 1990;27(1):21-31. PMID: 1690752.
  • Engelhardt JI, Appel SH, Killian JM. Experimental autoimmune motoneuron disease. Ann Neurol. 1989;26(3):368-76. PMID: 2802536.
  • Hayman LA, Taber KH, Jhingran SG, Killian JM, Carroll RG. Cerebral infarction: Diagnosis and assessment of prognosis by using 123IMP-SPECT and CT. AJNR Am J Neuroradiol. 1989;10(3):557-62. PMID: 2501987.
  • Ammenheuser MM, Ward JB, Jr, Whorton EB, Jr, Killian JM, et al. Elevated frequencies of 6-thioguanine-resistant lymphocytes in multiple sclerosis patients treated with cyclophosphamide: A prospective study. Mutat Res. 1988;204(3):509-20. PMID: 3347218.
  • Killian JM, Bressler RB, Armstrong RM, Huston DP. Controlled pilot trial of monthly intravenous cyclophosphamide in multiple sclerosis. Arch Neurol. 1988;45(1):27-30. PMID: 3276298.
  • Spitz MC, Jankovic J, Killian JM. Familial tic disorder, parkinsonism, motor neuron disease, and acanthocytosis: a new syndrome. Neurology. 1985;35(3):366-70. PMID: 3974894.
  • Killian JM, Kloepfer HW. Homozygous expression of a dominant gene for Charcot-Marie-Tooth neuropathy. Ann Neurol. 1979;5(6):515-22. PMID: 475348.
  • Alpert JN, Armbrust CA, Akhavi M, Stamatiou ES, Killian JM, De Shazo M. Glossopharyngeal neuralgia, asystole, and seizures. Arch Neurol. 1977;34(4):233-5. PMID: 320968.
  • Killian JM, Fromm GH. A double-blind comparison of nitrazepam versus diazepam in myoclonic seizure disorders. Dev Med Child Neurol. 1971;13(1):32-9. PMID: 4995285.
  • Killian JM. Tegretol in trigeminal neuralgia with special reference to hematopoietic side effects. Headache. 1969;9(1):58-63. PMID: 5804521.
  • Killian JM, Fromm GH. Carbamazepine in the treatment of neuralgia. Use of side effects. Arch Neurol. 1968;19(2):129-36. PMID: 4877400.
  • Fromm GH, Killian JM, Sanchez F, Jr. Observations on the discrepancy between the clinical and the laboratory effects of anti-petit mal drugs. Trans Am Neurol Assoc. 1967;92:238-40. PMID: 4999959.
  • Fromm GH, Killian JM. Effect of some anticonvulsant drugs on the spinal trigeminal nucleus. Neurology. 1967;17(3):275-80. PMID: 6066958.
  • Killian JM. Electromyography. In: Kass JS, Mizrahi EM, editors. Neurology secrets. 6th ed. Philadelphia: Elsevier; 2016. p. 467-473.
  • Killian JM. Electromyography. In: Rolak LA, editor. Neurology secrets. 5th ed. Philadelphia: Mosby; 2010. p. 428-435.
  • Bue B, Merényi E, Killian J. Classification and diagnosis of myopathy from EMG signals. Presented at the Society for Industrial and Applied Mathematics (SIAM), 13t h International Conference on Data Mining in Austin, Texas (May 2-4, 2013). [Platform Presentation]
  • Satija P, Clark G, Killian J. Diffuse painful muscle spasms. J Clin Neuromuscular Disease. 2008;9:374-5.
  • Sabbagh N, Smith RG, Lynn P, Doody RS, Appel SH, Killian JH. Pharmacologic evidence for autonomic sudomotor dysfunction in patients with Alzheimer’s disease. Neurology. 1996;46(2):A162.

KX2 Medical Mobility Equipment Supplier FAQ

What distinguishes KX2 as a leading medical device company?

KX2 Medical Devices stands out for its innovative approach to healthcare solutions, focusing on quality and patient-centric medical device products.

How does KX2 contribute to advancements in medical devices?

As one of the top medical device companies, KX2 is dedicated to pioneering advancements in medical mobility products, integrating cutting-edge technology and design.

What types of products are offered by KX2 Medical Devices?

KX2 specializes in a variety of medical mobility devices, including advanced foot drop braces and mobility assistance equipment designed to enhance patient independence and well-being.

What sets KX2 Devices apart from other companies medical devices?

As a dedicated medical device manufacturer, KX2 Devices stands out from other medical device companies in the USA for its commitment to quality, innovation, and creating products that genuinely meet the needs of our users.

Where can I find KX2 Medical Devices? Are there medical device companies near me that offer them?

KX2’s products are available only through their website. To find KX2 Medical Devices near you, visit our website, and we will ship directly to your location.

What quality standards does KX2 Medical Devices adhere to in manufacturing its products?

KX2 Medical Devices strictly adheres to international quality standards, including ISO 9001 and ISO 13485, ensuring each product has the same standards as the biggest American medical device companies.

What makes KX2 Medical Device Company different from other companies in the medical devices sector?

KX2 differentiates itself by combining compassionate care with innovation, offering products that significantly improve mobility and quality of life.

How can healthcare professionals collaborate with KX2 Medical Device Company?

Healthcare professionals can collaborate with KX2 by providing feedback, participating in product development, and utilizing KX2’s innovative solutions in patient care.

What is the future outlook for KX2 Medical Device Company among medical devices companies?

KX2 Medical Device Company is poised for continued growth and innovation, aiming to remain at the forefront of the medical devices sector by developing new solutions and expanding its product range.

No products in the cart